Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate

NCT03582475 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT03582475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03582475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 11, 2019
Completion date
December 1, 2026
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder small cell neuroendocrine carcinoma, castration-resistant prostate carcinoma, metastatic bladder urothelial carcinoma, metastatic urethral urothelial carcinoma, prostate carcinoma metastatic in the bone, prostate neuroendocrine neoplasm, prostate small cell carcinoma, stage iii bladder cancer american joint committee on cancer ( ajcc) v8, stage iii prostate cancer ajcc v8, stage iii urethral cancer ajcc v8, stage iv bladder cancer ajcc v8, stage iv prostate cancer ajcc v8, stage iv urethral cancer ajcc v8, stage iva bladder cancer ajcc v8, stage ivb bladder cancer ajcc v8, ureter small cell carcinoma, urothelial carcinoma